TITLE:
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor

CONDITION:
HIV Infections

INTERVENTION:
Amprenavir/ritonavir

SUMMARY:

      The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or
      saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second
      protease inhibitor based HAART.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion:

          -  Subject must remain on current antiretroviral therapy during screening until a new
             regimen is initiated.

          -  Subject demonstrates reduced susceptibility to lopinavir.

          -  Subject's two most recent viral loads obtained after at least 16 weeks of
             lopinavir/ritonavir therapy, and while still on Kaletra therapy must be at least
             1,000 copies/mL.

          -  The Kaletra regimen must be the subject's second PI containing regimen and must not
             contain any other PIs.

          -  Subject is at least 18 years of age.

          -  Subject has not been treated for an active opportunistic infection within 30 days of
             screening.

        Exclusion:

          -  Subject has a history of active substance abuse or psychiatric illness that could
             preclude compliance to the protocol.

          -  Female subject pregnant or lactating.

          -  Use of an Investigational drug within 30 days prior to the initiation of drug dosing.

          -  Subject is receiving systemic chemotherapy.

          -  Subject has a history of acute or chronic pancreatitis.
      
